The recent FDA approval of the PD‐L1 inhibitor pembrolizumab in advanced cancers with mismatch repair deficiency, regardless of site of origin, highlights the benefit of treatment stratification based on the molecular characteristics of tumours. The gene discussed is CD274; the disease is neoplasm.